Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiotequeROCO:4107 -0.44%84 Receivables Turnover is 2.37 as of Mar. 2026. GuruFocus rates ROCO:4107 with a GF Score™ of 84/100 and a GF Value™ of NT$130.11 (Modestly Undervalued). Among 811 Medical Devices & Instruments companies, Bioteque ranks better than 88.9% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Bioteque's Revenue for the
three
months ended in Mar. 2026 was NT$546 Mil. Bioteque's average Accounts Receivable for the
three
months ended in Mar. 2026 was NT$231 Mil.
Hence, Bioteque's Receivables Turnover for the
three
months ended in Mar. 2026 was 2.37.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Bioteque Receivables Turnover Related Terms
Bioteque Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Bioteque's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4107 vs ISRG, BDX, MDLN: Receivables Turnover Comparison
For the Medical Instruments & Supplies subindustry, Bioteque's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioteque Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bioteque's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Bioteque's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioteque (ROCO:4107) has a Receivables Turnover of 2.37 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Bioteque and its competitors. According to the industry distribution chart, Bioteque ranks #90 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 11.1%.
Is Bioteque's Receivables Turnover too high?
Bioteque's current Receivables Turnover is 2.37. The Medical Devices & Instruments industry median Receivables Turnover is 5.60. Bioteque's value of 2.37 is 57.7% below this industry median. Based on the distribution chart, Bioteque ranks #90 out of 811 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bioteque has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioteque's Receivables Turnover compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bioteque ranks #90 out of 811 companies for Receivables Turnover. This places Bioteque in the top 11% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.60. Bioteque's value of 2.37 is 57.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.60, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioteque's current Receivables Turnover of 2.37 is 57.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Bioteque and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioteque's current Receivables Turnover is 2.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioteque stock overvalued right now?
Based on GuruFocus' analysis, Bioteque (ROCO:4107) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$130.11, compared to a current price of NT$114.00 — trading 12.4% below its estimated fair value. The current Receivables Turnover is 2.37 and 57.7% below the Medical Devices & Instruments industry median of 5.60. Bioteque's overall GF Score™ is 84/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Bioteque (ROCO:4107), the current Receivables Turnover is 2.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioteque (ROCO:4107) Overvalued in 2026?
Based on GuruFocus' analysis, Bioteque stock appears to be undervalued.
The current stock price of NT$114.00 is trading 12.4% below its estimated GF Value™ of NT$130.11.
GuruFocus considers Bioteque to be Modestly Undervalued.
Key valuation signals for ROCO:4107:
Receivables Turnover: 2.37
GF Value™: NT$130.11 vs. price of NT$114.00 (12.4% below fair value)
Industry Position: 57.7% below the Medical Devices & Instruments median (#90 of 811)
No single metric tells the full story. See the ROCO:4107 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioteque Corp is engaged in manufacturing, trading, and selling medical equipment and instruments. The company operates in different segments such as Manufacturing medical disposables for hemodialysis use, and selling them to dealers and retailers; Manufacturing and selling catheters for healthcare and medical PVC IV bags to medical organizations; Manufacturing and selling medical key components and inner catheters to the medical organization; and Other segment. Geographically, the company generates a majority of its revenue from Asia and the rest from North America, South America, and other regions.
84GF Score
Get the complete analysis for ROCO:4107
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4107 has been successfully added to your 
